Skip to main content
OpenTrials
Enrolling by invitation

NCT Number: NCT07792044

Effect of Optimal Biological Volume Bupivacaine Liposome Interscalene Brachial Plexus Block on Postoperative Analgesia After Shoulder Arthroscopy

This study aims to evaluate whether 15ml/75mg low-dose bupivacaine liposome is non-inferior to 15ml/133mg standard-dose bupivacaine liposome for postoperative analgesia in interscalene brachial plexus block during arthroscopic shoulder surgery, through a single-center, prospective, double-blind, non-inferiority randomized controlled clinical trial. It will also assess whether 15ml/75mg low-dose bupivacaine liposome is superior to 15ml/133mg standard-dose bupivacaine liposome in terms of diaphragmatic excursion, pulmonary function, duration of block effect, and nerve block-related adverse reactions during interscalene brachial plexus block.

Enrolling by invitation

Interested in participating?

Request Info

Key information

Conditions

Pain and Diaphragmatic Dysfunction After Shoulder Arthroscopy Neurologic Manifestations Pain Pathologic Processes Pathological Conditions, Signs and Symptoms Respiration Disorders Respiratory Aspiration Respiratory Tract Diseases Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Jiaxing University Affiliated Hospital

Jiaxing, Zhejiang, 314000, China

About this study

This study is designed as a single-center, prospective, double-blind, non-inferiority randomized controlled clinical trial, to evaluate and compare whether the postoperative analgesic efficacy of 15 mL/75 mg low-dose liposomal bupivacaine for interscalene brachial plexus block in patients undergoing shoulder arthroscopy is non-inferior to that of 15 mL/133 mg standard-dose liposomal bupivacaine, and to further assess whether the low-dose regimen demonstrates advantages over the standard-dose counterpart in terms of diaphragmatic excursion, pulmonary function, duration of block effect, and nerve block-related adverse reactions.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients aged 18 years or older.
  • ASA classification I-III.
  • Arthroscopic shoulder rotator cuff repair, capsular plication, acromioplasty, synovectomy, etc.

Exclusion criteria

  • Have a history of lung disease.
  • Coagulation dysfunction or coagulopathy.
  • History of allergy to local anesthetics.
  • infection or lesions at the block site; or history of cervical spine disease.
  • pregnancy.
  • Refusal to participate in the study or inability to communicate.
  • Long-term use of opioids.
  • Body mass index >35 kg/m2
  • Previous history of nerve injury, paralysis, or paresis;

Treatment and study plan

OBV bupivacaine liposome group

Drug

Following our preliminary study protocol, 13 mL of liposomal bupivacaine (derived from the 20 mL/266 mg commercial formulation) is aspirated and further diluted with 0.9% sodium chloride injection to a final total volume of 53 mL while maintaining the fixed total dose of 266 mg. This diluted preparation is then combined with 2 mL of 0.5% conventional bupivacaine, and the resultant 55 mL mixture is administered to perform interscalene brachial plexus block prior to surgical incision.

Standard dose bupivacaine liposome group

Drug

Following the recommendations in published literature and the approved product labeling, 10 mL of liposomal bupivacaine (20 mL/266 mg formulation) is aspirated, combined with 2 mL of 0.5% conventional bupivacaine, diluted to a final total volume of 15 mL with 0.9% sodium chloride injection, and administered to perform ultrasound-guided interscalene

Primary outcomes

  1. Difference in numeric rating scale scores for resting pain at 24 hours after surgery

    Time frame: postoperative 24 hours

    Difference in numeric rating scale scores(0 = no pain, 10 = worst pain; higher numbers indicate greater pain intensity) for resting pain at 24 hours after surgery. Postoperatively, the NRS scale was used to evaluate pain scores.

Secondary outcomes

  1. Total consumption of morphine milligram equivalents within 72 hours postoperatively

    Time frame: within 72 hours postoperatively

    Record opioid analgesics within 72 hours postoperatively, convert to morphine equivalent dose, and calculate the total amount.

  2. Differences in numeric rating scale pain scores at rest and during activity within 0.5 hours, 6 hours, 24 hours, 48 hours, and 72 hours postoperatively

    Time frame: postoperative 0.5 hours, 6 hours, 24 hours, 48 hours, 72 hours

    Differences in numeric rating scale (0 = no pain, 10 = worst pain; higher numbers indicate greater pain intensity) pain scores at rest and during activity within 0.5 hours, 6 hours, 24 hours, 48 hours, and 72 hours postoperatively. Postoperatively, the NRS scoring scale was used to assess pain scores.

  3. Complete unilateral HDP during quiet breathing at 0.5 hours 6 hours, and 24 hours after completion of block

    Time frame: postoperative 0.5 hours, 6 hours and 24 hours

    A diaphragm excursion of >75% on the blocked side measured under ultrasound is defined as complete unilateral hemidiaphragmatic paralysis (HDP).

  4. Pulmonary function

    Time frame: postoperative 0.5 hours, 6 hours and 24 hours

    Use a portable respiratory function tester for bedside testing; have the patient blow three times and take the average.

  5. All adverse events related to surgery and anesthesia occurring within 72 hours postoperatively

    Time frame: within 72 hours postoperatively

    Adverse events associated with nerve blocks within 72 hours postoperatively, including pneumothorax, intravascular injection, local anesthetic toxicity, and Horner syndrome, were recorded.

  6. The number of rescue analgesic interventions required within 72 hours postoperatively

    Time frame: within 72 hours postoperatively

    The number of analgesic administrations within the first 72 hours postoperatively was recorded.

  7. sensorimotor score

    Time frame: postoperative 0.5 hours, 6 hours and 24 hours

    After completion of the block, the simplified sensorimotor assessment scale (3-point method) is used for evaluation, and a total sensorimotor score ≥12 points with a total sensory score ≥3 points is defined as successful brachial plexus block.

Sponsors and collaborators

Lead sponsor

Affiliated Hospital of Jiaxing University

Other

Registry information

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Aug 28, 2026
Registry last updated
Aug 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.